In order to determinate the necessity of TAK1 for USP13 to alleviate NAFLD, we adopted TAK1 inhibitor to treat USP13-KO mice, and the results indicated that inhibiting the TAK1 activation could neutralize the exacerbation of NAFLD brought from the deficiency of USP13. This evidence concerns the gene USP13 and metabolic dysfunction-associated steatotic liver disease.